10-K: Waters Corp. Reports 7% Sales Growth, Integrates BDS Business

Waters Corporation announced a 7% increase in net sales for 2025, alongside the transformative $16.8 billion acquisition of BD's Biosciences and Diagnostic Solutions businesses, significantly expanding its market presence.

Summary

• Net sales increased by 7% to $3.165 billion in 2025, following flat performance in 2024.
• Product sales grew 7% to $1.977 billion in 2025, while service sales increased 7% to $1.188 billion.
• Operating income decreased by 3% to $803 million in 2025, primarily due to $82 million in transaction and integration costs for the BDS Business Acquisition and $20 million for ERP system implementation.
• Net income saw a slight increase of 1% to $643 million in 2025, with diluted EPS at $10.76.
• Cash flow from operating activities decreased by 14.4% to $653 million in 2025, impacted by higher tax payments ($24 million), ERP costs ($52 million), and BDS acquisition costs ($29 million).
• Research and development expenses increased by 7% to $196 million in 2025, reflecting continued investment in new product development.
• The company completed the acquisition of Halo Labs for $35 million in cash in May 2025, enhancing particle analysis capabilities.
• Waters Corporation completed the acquisition of BD's Biosciences and Diagnostic Solutions (BDS) businesses on February 9, 2026, for a total purchase price of $16.8 billion, including assumed debt.
• The BDS Business Acquisition was structured as a Reverse Morris Trust transaction, resulting in BD shareholders owning approximately 39.2% of the combined company and existing Waters shareholders owning 60.8%.
• The company assumed $4.0 billion of indebtedness from SpinCo (related to the BDS acquisition), with $3.5 billion maturing in February 2027 and $500 million in February 2028.
• The company plans to refinance the $3.5 billion tranche with long-term bond financing in Q1 2026 and repay the $500 million tranche prior to maturity.
• A new worldwide ERP system implementation is underway, with an anticipated total spend of $130 million, of which $52 million has been spent through 2025.
• The share repurchase program was extended through January 21, 2028, with $1.0 billion remaining authorization; no open market repurchases were made in 2024 or 2025.
• Sales to pharmaceutical customers increased 9% in 2025, while industrial sales grew 6%, and academic and government sales were flat.
• Geographically, China sales increased 10% in 2025 after a 10% decline in 2024, and Europe sales grew 10% in 2025.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a strategically ambitious but financially challenging period. While sales growth is positive and the BDS acquisition is transformative, the immediate impact on operating income and cash flow due to integration costs and increased debt introduces near-term headwinds and execution risk.

Positives

• Net sales increased by a strong 7% in 2025, driven by broad-based customer demand across most major geographies and product lines.
• Both product sales and service sales demonstrated solid 7% growth in 2025.
• Waters chemistry consumables achieved double-digit sales growth (12%) in 2025, particularly from pharmaceutical customers.
• China sales rebounded with a 10% increase in 2025, reversing a 10% decline in 2024.
• Europe sales also showed strong growth, increasing by 10% in 2025.
• The acquisition of Halo Labs in May 2025 for $35 million expands particle analysis capabilities, complementing existing Wyatt Technology offerings.
• The transformative BDS Business Acquisition establishes Waters as an innovative global leader in life sciences and diagnostics, broadening capabilities and market presence.
• The company reduced its total debt outstanding to $1.4 billion in 2025 from $1.6 billion in 2024, prior to the BDS acquisition debt assumption.
• Cash and cash equivalents increased significantly to $588 million at December 31, 2025, from $325 million in 2024.
• The company maintains a robust share repurchase program with $1.0 billion remaining authorization, demonstrating commitment to shareholder returns.
• Management reports effective internal control over financial reporting as of December 31, 2025.

Negatives

• Operating income decreased by 3% in 2025, primarily due to significant transaction and integration costs related to the BDS Business Acquisition ($82 million) and ERP system implementation expenses ($20 million).
• Cash flow from operating activities decreased by $109.6 million in 2025, driven by higher tax payments, ERP costs, and BDS acquisition-related payments, suggesting a less favorable cash generation than prior year.
• The Singapore tax incentive benefit of $4 million in 2025 was substantially reduced by $14 million due to the global minimum tax under Pillar Two.
• Industrial sales in the U.S. declined by 5% in 2025 due to lower demand for TA instrument systems.
• Unrealized losses on interest rate cross-currency swap agreements were substantial at $86.7 million in 2025, primarily due to foreign exchange rate changes.
• The company incurred $16 million in financing costs on behalf of SpinCo related to the BDS Business Acquisition in 2025, and an additional $5 million in February 2026 from the cancellation of a bridge facility.

Risks

• Failure to successfully integrate the BDS Business within the expected timeline could adversely affect future results, including lost sales and customers, inability to negotiate favorable contract terms, and challenges in managing a larger, more complex business.
• The company may incur additional costs and charges from restructuring activities related to manufacturing, supply chain, and business function streamlining, which may be disruptive and not result in anticipated cost savings.
• The substantial indebtedness assumed from the BDS Business Acquisition ($4.0 billion) could adversely affect operational flexibility, increase borrowing costs, and limit the ability to make dividend payments or secure other indebtedness.
• Restrictions imposed by the Tax Matters Agreement related to the BDS Business Acquisition could limit the company's ability to undertake certain corporate actions and result in material tax liabilities if violated.
• Inability to provide or obtain the same types and level of services for the BDS Business that BD historically provided, or at the same cost, could materially adversely impact results of operations.
• International operations are exposed to negative impacts from political events, wars or terrorism, economic conditions and regulatory changes, related to either a specific country or a larger region, which could have a material adverse effect on results of operations or financial condition.
• Global economic conditions, including inflation and interest rates, may adversely affect demand for and supply of products, leading to declining sales, increased order cancellations, or inventory issues.
• Disruption in worldwide financial markets could impair access to capital and increase borrowing costs.
• Changes in customer demand, capital spending, governmental regulations, and funding for research institutions can adversely affect financial results.
• Competitors may introduce more effective or less expensive products, or industry consolidation may transform the competitive landscape, leading to decreased sales and market share loss.
• Strategies for organic growth require significant time and investment in new technologies, with no assurance of market acceptance or timely development.
• Defects or quality issues in products, including software or hardware, could lead to recalls, product liability claims, regulatory actions, and reputational damage.
• Issues and uncertainties related to the development, deployment and use of artificial intelligence (AI) in the company's business operations and products may result in harm to reputation, regulatory action or legal liability.
• Risks associated with previous or future acquisitions, strategic investments, joint ventures, and divestitures, including integration difficulties, diversion of management attention, and potential dilution.
• Disruption of operations at manufacturing facilities or failure of key technology systems (e.g., ERP system implementation) could materially impact business, results of operations, and financial condition.
• Failure to adequately protect intellectual property, or infringement of third-party rights, could materially adversely affect results of operations.
• Inability to acquire adequate sources of supply for raw materials and components, or disruptions in the supply chain, could harm business and customer relationships.
• Failure of outside contractors to provide necessary components or intellectual property development could deteriorate sales.
• Actions of third-party sales intermediaries and resellers, including competitive pressure, concentration of sales volumes, credit risks and compliance risks, could harm the business.
• Failure to comply with laws and regulations governing government contracts could lead to penalties or reduced revenues.
• Changes in tax law and tax audit examinations, including the global minimum tax rules (Pillar Two) and the OBBBA, could adversely affect cash flow and profitability.
• The company may be required to recognize impairment charges for goodwill and other intangible assets, especially after the significant increase from the BDS Business Acquisition.
• Failure to attract or retain qualified personnel, including senior management and technical staff, could lead to loss of revenue or profitability.
• Labor disruptions, particularly in foreign jurisdictions where employees are represented by works councils or unions, could result in production delays or higher costs.
• Cybersecurity incidents, data breaches, or failures in security measures could damage reputation, disrupt services, and lead to legal claims and regulatory actions.
• Changes in governmental regulations and compliance failures, particularly in health and safety, antitrust, fraud and abuse, import/export, privacy, and anti-bribery laws, could harm the business.
• Improper conduct by employees, agents or business partners could damage reputation and subject the company to civil or criminal investigations.
• Sustainability issues, including those related to climate change, may have an adverse effect on business, financial condition and results of operations and damage reputation.
• Litigation and other legal and regulatory proceedings in the ordinary course of business can divert management attention and result in unfavorable resolutions.
• Exclusive forum provisions in the Bylaws and other anti-takeover provisions in the Charter and Bylaws could limit shareholders' ability to obtain a favorable judicial forum or delay/discourage takeover attempts.

Future Outlook

The company anticipates continued investment in new product development and existing product enhancements. It expects to generate cost synergies of approximately $200 million within three years and revenue synergies of approximately $290 million within five years from the BDS Business Acquisition. The $3.5 billion tranche of assumed debt from the BDS acquisition is planned to be refinanced with long-term bond financing in Q1 2026, and the $500 million tranche is expected to be repaid prior to maturity. The company is assessing the future impact of additional OECD guidance on Pillar Two global minimum tax rules and will continue to monitor the impact of the OBBBA.

Management Comments

• "The net sales growth in 2025 reflected strong customer demand for the Waters Division products and services across most major geographies, end markets and product lines."
• "The double-digit chemistry sales growth can be attributed to the uptake in columns and application-specific testing kits to pharmaceutical customers."
• "The increase in research and development expenses in 2025 can be attributed to increases from costs associated with merit compensation to the Companys employees and costs associated with new products and the development of new technology initiatives."
• "Management believes, as of the date of this report, that the Companys financial position, along with expected future cash flows from earnings based on historical trends and the ability to raise funds from external sources and the borrowing capacity from existing, committed credit facilities, will be sufficient to service debt and fund working capital and capital spending requirements, authorized share repurchase amounts and potential acquisitions for at least the next twelve months."
• "We believe that our people differentiate our business and are vital to our continued success."
• "We believe inclusion is a core tenet of organizational success and that fostering a sense of inclusivity allows our employees to maximize their performance contribution to our business."
• "The health and safety of our employees is our highest priority."
• "The Company believes it has meritorious arguments in its current litigation matters and believes any outcome, either individually or in the aggregate, will not be material to the Companys financial position or results of operations."
• "Our management is responsible for establishing and maintaining adequate internal control over financial reporting... concluded that our internal control over financial reporting was effective as of December 31, 2025."

Industry Context

StockSavvy.ai notes that Waters Corporation's strategic acquisition of BD's Biosciences and Diagnostic Solutions businesses positions it as a more diversified leader in the life sciences and diagnostics sector, moving beyond its traditional chromatography and mass spectrometry core. This expansion into clinical diagnostics and broader immunology/cancer research solutions aligns with a broader industry trend of convergence in analytical and diagnostic technologies. The company's continued investment in R&D and new product introductions, such as advanced LC-MS systems and particle analysis tools, reflects the high-innovation, competitive nature of the analytical instrument market, where companies like Agilent, Shimadzu, and Thermo Fisher Scientific are also active. The challenges faced in the China market due to government regulations and economic conditions are a common theme for global players in this region, highlighting geopolitical and trade risks.

Comparison to Industry Standards

• Waters Corporation's 7% net sales growth in 2025 is a solid performance, especially when compared to its flat growth in 2024, indicating a recovery in demand for its analytical instruments and services. This growth rate should be benchmarked against the average growth of its key competitors like Agilent Technologies, Shimadzu Corporation, and Thermo Fisher Scientific Inc. in their respective analytical instrument and life science segments.
• The decline in operating income by 3% in 2025, despite revenue growth, is notable. This is attributed to significant acquisition and ERP implementation costs. Industry peers undertaking similar large-scale integrations or system upgrades often experience temporary margin compression, but the extent and duration would need to be compared to specific examples from competitors' past filings.
• The assumed $4.0 billion in new indebtedness from the BDS Business Acquisition significantly alters Waters' capital structure. A detailed comparison of its post-acquisition debt-to-EBITDA and interest coverage ratios against industry averages for companies in the life sciences and diagnostics sector, particularly those that have recently completed large acquisitions (e.g., Danaher's past acquisitions in life sciences), would provide critical context on its financial leverage.
• The 10% sales growth in China in 2025, following a 10% decline in 2024, suggests a volatile but potentially recovering market. This performance should be compared to how other multinational analytical instrument companies have navigated the challenging Chinese market, especially concerning government procurement restrictions and local competition.
• The company's R&D expenditure of $196 million in 2025, representing approximately 6.2% of net sales, is a key indicator of its commitment to innovation. This percentage should be compared to the R&D intensity of its direct competitors to assess its competitive positioning in product development.
• The effective internal control over financial reporting, as attested by management and audited by PricewaterhooCoopers LLP, meets industry best practices and regulatory requirements under Sarbanes-Oxley Act.

Management Changes

Corporate Governance

Legal Proceedings

• The company and its subsidiaries are involved in various lawsuits, claims, investigations, and proceedings in the ordinary course of business.
• Management believes it has meritorious arguments in current litigation matters and that any outcome, individually or in aggregate, will not be material to the company's financial position or results of operations.
• Recorded $12 million of patent litigation settlement provisions and related costs in 2024; no litigation provisions were recorded in 2025.

Stakeholder Impact

• Shareholders: Potential for dilution from the BDS Business Acquisition (BD shareholders now own 39.2% of the combined company). The success of the integration and realization of synergies will significantly impact future shareholder value. Anti-takeover provisions in corporate governance documents may limit shareholder actions.
• Employees: Workforce reductions in 2023 and 2024 (5% and 2% respectively) could impact morale and productivity. The BDS Business Acquisition will lead to reorganization into four new segments, potentially affecting roles and responsibilities. Talent attraction and retention remain critical, especially for specialized engineering and technical personnel.
• Customers: The BDS Business Acquisition expands product offerings into new areas like diagnostics and broader life sciences, potentially offering a more comprehensive solution portfolio. However, integration challenges could temporarily affect service levels or product availability. Demand is sensitive to customer capital spending, government funding, and macroeconomic conditions.
• Creditors: The assumption of $4.0 billion in new indebtedness from the BDS Business Acquisition significantly increases the company's leverage, impacting credit risk and borrowing costs. Compliance with financial covenants in credit agreements is crucial.
• Suppliers: Supply chain disruptions, raw material availability, and price increases (including tariffs) could impact manufacturing costs and product delivery. The company's reliance on limited or single sources for certain specialized products poses a risk.
• Regulatory Authorities: Increased regulatory burdens are expected as the business evolves, particularly with respect to the U.S. Food and Drug Administration and U.S. Environmental Protection Agency, and in connection with government contracts. Compliance with data privacy, information security, and anti-bribery laws is critical.

Next Steps

• Integrate the BDS Business with existing operations to realize anticipated cost synergies of approximately $200 million within three years and revenue synergies of approximately $290 million within five years.
• Refinance the $3.5 billion tranche of assumed debt from the BDS acquisition with long-term bond financing in Q1 2026.
• Repay the $500 million tranche of assumed debt prior to its maturity.
• Continue the multi-year implementation of the new worldwide ERP system, with an anticipated total spend of $130 million.
• Evaluate business activities to determine operating and reporting segments for future reporting periods following the BDS Business Acquisition.
• Monitor the impact of the One Big Beautiful Tax Bill Act (OBBBA) in future periods.
• Assess the future impact of additional OECD guidance on Pillar Two global minimum tax rules.
• File the 2025 Form SD with the SEC in May 2026 regarding conflict minerals.

Key Dates

Recommendation

The company demonstrates solid underlying sales growth in 2025 and has made a transformative acquisition with the BDS Business. This acquisition significantly expands its market reach and capabilities, offering long-term growth potential. However, the immediate financial impact includes a decline in operating income due to substantial integration and ERP implementation costs, a decrease in operating cash flow, and the assumption of $4.0 billion in new debt. These factors introduce considerable execution risk and near-term financial pressure. While the strategic rationale is strong, the successful integration and realization of anticipated synergies are critical and uncertain. Therefore, a 'hold' recommendation is appropriate, reflecting a balanced view of the company's strategic strengths and the significant integration and financial risks ahead.

Keywords

Waters Corporation, WAT, SEC Filing, 10-K, Annual Report, Life Sciences, Diagnostics, Analytical Instruments, Chromatography, Mass Spectrometry, Thermal Analysis, HPLC, UPLC, LC-MS, TA Instruments, Wyatt Technology, Halo Labs, BD Biosciences, BDS Business Acquisition, Mergers and Acquisitions, Financial Performance, Revenue Growth, Operating Income, Net Income, EPS, Cash Flow, Debt, Capital Raise, ERP System, Share Repurchase, Pharmaceutical Industry, Biotechnology, Laboratory Equipment, Consumables, Service Revenue, International Operations, China Market, Europe Market, Taxation, Pillar Two, OBBBA, Intellectual Property, Supply Chain, Cybersecurity, Corporate Governance, Risk Factors, Sustainability, Human Capital